Cystetic Medicines

In the 4th quarter of 2020, Deerfield led the Series A in Cystetic Medicines. Cystetic is based on the work and intellectual property developed by Dr. Martin Burke at the University of Illinois and is focused on creating novel inhaled therapeutics to restore the ion balance in the lungs to treat cystic fibrosis patients. The restoration of ion balance serves to restore lung function and could be useful in fungal infections.